Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$164.82 USD
-1.33 (-0.80%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $164.97 +0.15 (0.09%) 7:38 PM ET
4-Sell of 5 4
C Value F Growth D Momentum D VGM
Price, Consensus and EPS Surprise
JNJ 164.82 -1.33(-0.80%)
Will JNJ be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JNJ
Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy?
ISRG Stock Rallies 14% in 3 Months: Is It Still Worth Buying?
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?
Other News for JNJ
RYBREVANT? (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
2024 ISPE Pharma 4.0? and Annex 1 Conference Featured Speakers Are Announced
Prevent Blindness Names Howard Purcell, O.D., New England College of Optometry, as the 2025 Person of Vision Award Recipient
'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale
JNJ December 20th Options Begin Trading